# US 2016/0256539 A1 · HIV-1 ENV DNA Vaccine Plus Protein Boost Delivered by EP Expands B- and T-Cell Response and Neutralizing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256539 A1
- Document ID: US20160256539A1
- Status: Published application
- Kind: A1
- Application number: 15/035,793
- Filed: 2014-11-06
- Published: 2016-09-08
- Earliest claimed: 2013-11-14
- Assignees: The Trustees of the University of Pennsylvania; Inovio Pharmaceuticals, Inc.
- Applicants: The Trustees of the University of Pennsylvania; Inovio Pharmaceuticals, Inc.
- Inventors: David Weiner; Karuppiah Muthumani; Megan Wise; Jian Yan; Kate Broderick
- Web page: https://patentgrep.com/patent/US20160256539A1

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61P 31/18: for HIV
- A61K 39/12: Viral antigens
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/575: {humoral response}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16171: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention is directed to an effective HIV vaccine will most likely require the induction of strong T-cell responses, broadly neutralizing antibodies (bNAbs), and the elicitation of antibody-dependent cellular cytotoxicity (ADCC). Previously, we demonstrated the induction of strong HIV/SIV cellular immune responses in macaques and humans using synthetic consensus DNA immunogens delivered via adaptive electroporation (EP). However, the ability of this improved DNA approach to prime for relevant antibody responses has not been previously studied. Here, we investigate the immunogenicity of consensus DNA constructs encoding gp140 sequences from HIV-1 subtypes A, B, C and D in a DNA prime protein boost vaccine regimen. Mice and Guinea pigs were primed with single and multi-clade DNA via EP and boosted with recombinant gp120 protein. Sera were analyzed for gp120 binding and induction of neutralizing antibody activity. Immunization with recombinant Env protein alone induced low-titer binding antibodies with limited neutralization breath. In contrast the synthetic DNA prime protein boost protocol was induced significantly higher antibody binding titers. Furthermore, sera from DNA prime-protein boost groups were able to neutralize a broader range of viruses in a panel of tier 1 clade B viruses as well as multiple tier 1 clade A and clade C viruses. Further investigation of synthetic DNA prime+adaptive EP plus protein boost appears warranted.

## Claims

### Claim 1

A composition comprising
(a) a first vaccine, wherein the first vaccine comprises at least one, at least two, at least three, or at least four nucleic acids, wherein each nucleic acid encodes an antigen, and wherein the at least one, at least two, at least three, or at least four nucleic acids are selected from the group consisting of a nucleic acid encoding a HIV-1 subtype A consensus antigen, a nucleic acid encoding a HIV-1 subtype B consensus antigen, a nucleic acid encoding a HIV-1 subtype C consensus antigen, a nucleic acid encoding a HIV-1 subtype D consensus antigen, and any combination thereof; and
(b) a second vaccine, wherein the second vaccine comprises at least one, at least two, at least three, or at least four antigenic peptides, and wherein the at least one, at least two, at least three, or at least four antigenic peptides are selected from the group consisting of a HIV-1 subtype A consensus peptide, a HIV-1 subtype B consensus peptide, a HIV-1 subtype C consensus peptide, a HIV-1 subtype D consensus peptide, and any combination thereof.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the at least two nucleic acids of the first vaccine comprises
(a) a first nucleic acid encoding a HIV-1 subtype A consensus antigen, a HIV-1 subtype B consensus antigen, a HIV-1 subtype C consensus antigen, or a HIV-1 subtype D consensus antigen, and
(b) a second nucleic acid encoding a HIV-1 subtype A consensus antigen, a HIV-1 subtype B consensus antigen, a HIV-1 subtype C consensus antigen, or a HIV-1 subtype D consensus antigen.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the at least three nucleic acids of the first vaccine comprises:
(a) a first nucleic acid encoding a HIV-1 subtype A consensus antigen, a HIV-1 subtype B consensus antigen, a HIV-1 subtype C consensus antigen, or a HIV-1 subtype D consensus antigen,
(b) a second nucleic acid encoding a HIV-1 subtype A consensus antigen, a HIV-1 subtype B consensus antigen, a HIV-1 subtype C consensus antigen, or a HIV-1 subtype D consensus antigen; and
(c) a third nucleic acid encoding a HIV-1 subtype A consensus antigen, a HIV-1 subtype B consensus antigen, a HIV-1 subtype C consensus antigen, or a HIV-1 subtype D consensus antigen.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the at least four nucleic acids of the first vaccine comprises
(a) a first nucleic acid encoding a HIV-1 subtype A consensus antigen, a HIV-1 subtype B consensus antigen, a HIV-1 subtype C consensus antigen, or a HIV-1 subtype D consensus antigen;
(b) a second nucleic acid encoding encoding a HIV-1 subtype A consensus antigen, HIV-1 subtype B consensus antigen, a HIV-1 subtype C consensus antigen, or a HIV-1 subtype D consensus antigen;
(c) a third nucleic acid encoding a HIV-1 subtype A consensus antigen, a HIV-1 subtype B consensus antigen, a HIV-1 subtype C consensus antigen, or a HIV-1 subtype D consensus antigen; and
(d) a fourth nucleic acid encoding a HIV-1 subtype A consensus antigen, a HIV-1 subtype B consensus antigen, a HIV-1 subtype C consensus antigen, or a HIV-1 subtype D consensus antigen.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the antigen of the first vaccine is selected from the group consisting of Env A, Env B, Env C, Env D, B Nef-Rev, Gag, gp120 and gp140.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the antigen of the second vaccine is selected from the group consisting of Env A, Env B, Env C, Env D, B Nef-Rev, Gag, gp120 and gp140.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the antigenic peptide of the first vaccine is gp140.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the antigenic peptide of the second vaccine is gp120.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the first vaccine is a priming vaccine.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the second vaccine is a boosting vaccine.

### Claim 11 (depends on 1)

A method of immunizing a subject in need thereof against HIV-1, the method comprising administering the composition of claim 1 to the subject, wherein the first vaccine is administered independently of the second vaccine.

### Claim 12 (depends on 11)

The method of claim 11, wherein first vaccine is administered at a first time, and wherein the first time is day 1 of a vaccination regimen.

### Claim 13 (depends on 12)

The method of claim 12, wherein the first vaccine is administered at a second time, and wherein the second time is within 12 hours, 24 hours, 36 hours, or 48 hours of the first time of the first vaccine.

### Claim 14 (depends on 13)

The method of claim 13, wherein the first vaccine is a priming vaccine.

### Claim 15 (depends on 11)

The method of claim 11, wherein the second vaccine is administered about 48 hours to about 15 weeks, about 48 hours to about 10 weeks, about 48 hours to about 5 weeks, or about 48 hours to about 1 week after the first vaccine.

### Claim 16 (depends on 11)

The method of claim 11, wherein the second vaccine is administered at least about 48 hours, at least about 90 hours, at least about 2 weeks, at least about 5 weeks, or at least about 10 weeks after the first vaccine.

### Claim 17 (depends on 11)

The method of claim 11, wherein the second vaccine is administered a second time, and wherein the second time is about 48 hours to about 15 weeks, about 48 hours to about 10 weeks, about 48 hours to about 5 weeks, or about 48 hours to about 1 week after the first administration of the second vaccine.

### Claim 18 (depends on 11)

The method of claim 11, wherein the second vaccine is administered a second time, and wherein the second time is at least about 48 hours, at least about 90 hours, at least about 2 weeks, at least about 5 weeks, or at least about 10 weeks after the first administration of the second vaccine.

### Claim 19 (depends on 11)

The method of claim 11, wherein the first vaccine is administered 1 time, 2 times, 3 times, 4 times, or 5 times, each administration of the first vaccine being spaced in time from the other administrations of the first vaccine.

### Claim 20 (depends on 9)

The method of claim 9, wherein the second vaccine is administered 1 time, 2 times, 3 times, 4 times, or 5 times, each administration of the second vaccine being spaced in time from the other administrations of the second vaccine.
